东诚药业(002675) - 2021 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2021 was ¥890,215,161.87, representing a 24.76% increase compared to ¥713,529,257.18 in the same period last year[8]. - Net profit attributable to shareholders decreased by 9.44% to ¥66,898,146.52 from ¥73,869,412.29 year-on-year[8]. - Basic earnings per share decreased by 9.45% to ¥0.0834 from ¥0.0921 in the same period last year[8]. - Operating revenue increased by 24.76% year-on-year, reaching approximately ¥890.22 million, driven by a 16.80% increase in raw material drug revenue and an 89.40% increase in nuclear medicine revenue[21]. - The net profit after deducting non-recurring gains and losses was ¥64,315,324.03, a decrease of 10.47% from ¥71,835,903.22 year-on-year[8]. - The total comprehensive income attributable to the parent company was ¥65,388,801.62, down from ¥72,744,477.85 in the previous period[72]. - The net profit for the first quarter of 2021 is not explicitly stated in the provided documents, but the increase in retained earnings to CNY 1,217,410,369.68 from CNY 1,150,512,223.16 suggests positive performance[53]. - The net profit for the current period was ¥4,198,514.97, a significant decrease of 91.4% from ¥49,025,755.50 in the previous period[76]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 43.83% to ¥148,325,209.80 compared to ¥103,123,371.14 in the previous year[8]. - Cash received from tax refunds increased by 98.85% year-on-year, driven by growth in export volumes[22]. - The company reported a cash inflow from operating activities of ¥873,926,710.76, compared to ¥767,580,167.37 in the previous period[84]. - The company incurred a net cash outflow from investing activities of ¥102,477,319.83, an improvement from a net outflow of ¥406,734,501.24 in the previous period[84]. - The company reported a net increase in cash and cash equivalents of ¥31,523,304.14, contrasting with a decrease of ¥228,605,641.80 in the previous period[86]. - The ending balance of cash and cash equivalents was ¥745,045,657.78, compared to ¥587,864,522.47 in the previous period, marking an increase of approximately 26.8%[86]. - Total cash inflow from operating activities increased to ¥383,900,494.53, up from ¥315,079,891.41, representing a growth of about 21.7%[87]. - Cash flow from operating activities for the current period was ¥31,881,183.87, a decrease from ¥39,442,915.16 in the previous period, reflecting a decline of approximately 19.5%[87]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,558,464,112.82, a 2.24% increase from ¥7,393,206,198.64 at the end of the previous year[8]. - Total liabilities increased to CNY 2,497,803,098.96 from CNY 2,427,549,240.76, which is an increase of about 2.88%[50]. - The company's current assets totaled CNY 3,018,176,034.90, up from CNY 2,945,107,643.29, indicating an increase of about 2.24%[44]. - Total current liabilities amounted to ¥1,897,003,393.95, with short-term borrowings at ¥457,062,451.31 and accounts payable at ¥186,158,794.75[96]. - Total non-current liabilities were ¥530,545,846.81, including long-term borrowings of ¥448,532,879.32 and lease liabilities of ¥36,386,055.24[96]. - Total equity attributable to shareholders of the parent company reached CNY 4,533,423,531.82, up from CNY 4,468,323,480.21, indicating a growth of approximately 1.46%[53]. Operating Costs and Expenses - The company's operating costs increased by 38.79% compared to the same period last year[19]. - Research and development expenses rose by 69.77% year-on-year, primarily due to increased investment in R&D[21]. - Financial expenses surged by 970.66% year-on-year, mainly due to increased interest expenses[22]. - The company's inventory decreased to CNY 931,959,846.41 from CNY 974,026,852.86, showing a decline of approximately 4.3%[44]. - Total operating costs amounted to CNY 781,277,681.37, up from CNY 612,366,510.00 in the previous period, indicating rising expenses[65]. - Research and development expenses for the current period were CNY 31,104,349.40, up from CNY 18,321,598.11, highlighting a focus on innovation[65]. Shareholder Information - The total number of shareholders at the end of the reporting period was 23,975[12]. - The company's net assets attributable to shareholders increased by 1.46% to ¥4,533,423,531.82 from ¥4,468,323,480.21 at the end of the previous year[8]. - The total equity of the company increased to CNY 3,949,404,198.02 from CNY 3,945,205,683.05, indicating stable shareholder value[60]. Investments and Strategic Initiatives - The company was re-certified as a high-tech enterprise, valid for three years, enhancing its innovation capabilities[26]. - The company signed an agreement to invest $18.07 million in APRINOIA Therapeutics Inc., acquiring 16% of the company post-investment[26]. - The total investment for the nuclear pharmacy construction project was adjusted to ¥193 million, with cumulative investment reaching ¥127.46 million, representing 66.04% of the planned investment[33].